Brought to you by 
Recordati SpA
http://www.recordati.com/
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Recordati SpA
No English Funding For Lymphoma Drugs Ledaga and Poteligeo
Limitations in the design of the clinical trials that were carried out for each drug are among the concerns highlighted by the health technology assessment body in two interim guidances that are now out for consultation.
Recordati Raises Forecast for Isturisa After Smooth Launches
The Italian firm's move to license Isturisa from Novartis last year is paying dividends already and Recordati has already tripled its peak sales forecast for the Cushing's therapy.
Fortacin: EMA Recommends Fifth EU-Wide Rx-to-OTC Switch
Premature ejaculation treatment Fortacin is set to become only the fifth drug to achieve an Rx-to-OTC switch through European Medicines Agency's centralized procedure, expanding the burgeoning OTC men's sexual health category.
Company Information
- Industry
- Distributors
- Pharmaceuticals
-
Pharmaceuticals
- OTC, Consumer
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- Bouchara Recordati
- Dr. F. Frik Ilaç A.S.
- Opalia Pharma S.A.
- Orphan Europe
- Recordati Pharmaceuticals Ltd.
- Laboratorios Casen Fleet
- Italchimici S.p.A.
- Pro Farma AG
- Recordati S.A. Chemical and Pharmaceutical Company
- Recordati Rare Diseases Canada Inc.
- Natural Point S.r.l.
- Tonipharm S.A.S.